Find a Clinical Trial
At Torrance Memorial Physician Network - Cancer Care, we are committed to the advancement of effective new cancer therapy.
Active Trials TRIO-US
The following clinical trials are available at Torrance Memorial Physician Network - Cancer Care in coordination with the TRIO-US/Clinical Trials Network. This is a unique opportunity for patients in the South Bay to receive advanced research treatments previously restricted to university cancer centers. TRIO-US/Clinical Trials Network affiliated program places Torrance Memorial Physician Network patients into the promising new era of cancer treatment research. All patients enrolled in these trials are treated at our infusion center in Redondo Beach.
The following studies are subject to change by TRIO-US/Clinical Trials Network and the participating pharmaceutical companies and may not be continually or currently open. Enrollment and participation in these studies is voluntary and patients can choose to withdraw at any time and for any reason. All experimental study drugs are provided at no charge.
Each study has precise entry criteria for enrollment because the researchers are attempting to answer a specific treatment question, within a specific clinical parameter, so not all interested patients will be eligible to participate. It is notable that most of the studies involve drugs that are pathway-specific or targeted, which has been a major trend in cancer research over the past decade as the molecular secrets of cancer growth are revealed.
| Disease | Title | Summary | Status | Investigator |
| Breast Cancer | CONTESSA: ODO-TE-B301A. Odonate/inVentive | Phase 3 Study of Tesetaxel(PO) plus reduced dose of Capecitabine(PO) vs Capecitabine alone in patients with HR (+), HER2 (-), locally advanced or metastatic breast cancer, previously treated with a taxane. | Open/Active | Swati Sikaria, MD |
| Breast Cancer | EMERALD: RAD1901-308 | ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE (ENDOCRINE THERAPY) FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL. | Open/Active | David Chan, MD |
| Colorectal Cancer | NOVA:CG001, Clinical Genomics/Beaufort | Only one blood collection is required for enrollment. Followed by ONE scan/test (CT/MRI/PET/endoscopy). Must be in remission from Stage II/III CRC and within 6 mos-24 months after treatment, with no evidence of disease, no other current cancer. Blood draw to be done within 6 months prior to scan, or on day of, but not after contrast agents. | Open/Active | David Chan, MD |
| GI Cancer | PASCAL: CG013, Clinical Genomics/Beaufort | Enrolling reoccurrance arm only. Only one blood collection is required within 4 weeks of SCAN. Must be in remission from Stage II/III CRC and within 6 mos-24 months after treatment, with no evidence of disease, no other current cancer. Coincides with NOVA. | Open/Active | David Chan, MD |
| Lung Cancer | VISION: MS200095-0022 Merck/Quintiles |
Pre-screening site only. Phase II 2nd/3rd line – Stage IV NSCLC- all histology included- ALK/EGFR Negative. Must not have received more than two lines of therapy. Seeking archival tissue for MET exon 14 testing***. MET AMP/MET exon 14 testing is available using Guardant 360 blood draw. Either archival tissue and/or Guardant may be used, MD discretion. ***If positive for MET AMP/exon 14 then pt will be referred to City of Hope for treatment arm of trial. |
Open/Active | Andrew Horodner, MD |
| All Solid Tumor | LexentBio: LB-1985106 | All solid tumors. No lymphoma or heme. Currently enrolling ONLY New Dx/Progression- UNRESECTABLE. Patients will be enrolled before the start of any new therapy (targeted, endocrine, chemotherapy, radiation, etc.) Blood (20mLs-2 tubes) will be collected before the start of any treatment and collected every 3-4 weeks depending on treatment cycle. Subject can stay on study until progression, etc. | Open/Active | David Chan, MD |
Active Trials - UCLA Trials
The following clinical trials are available at Torrance Memorial Physician Network - Cancer Care and are in coordination with the TRIO-US / Clinical Trials Network.
| Disease | Title | Summary | Status | Investigator |
| Breast Cancer ‐ ADJUVANT (ER +, HER2 neg) | TRIO 033 ‐ Novartis CLEE011O12301C "NATALEE" | Phase III, multicenter, randomized, open‐label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor‐positive, HER2‐negative, early breast cancer (New Adjuvant TriAl with Ribociclib.[LEE011]:NATALEE) | Open/Active | David Chan, MD |
| Pancreatic Cancer | ARMO AM0010‐301 SEQUOIA | A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second‐line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First‐Line Gemcitabine Containing Regimen | Open/Active | Hugo Hool, MD |
| Colorectal Cancer | Abbvie M14‐064 | Phase 2 Study Comparing Efficacy and Safety of ABT‐165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab. | Open/Active | Thomas Lowe, MD |
| Lymphoma | Incyte INCB 50465‐204 (CITADEL‐204) | Open Label 2‐Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor. | Open/Active | Swati Sikaria, MD |
| Lung Cancer | BMS CA209‐817 NSCLC (CHECKMATE 817) | A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Lung Malignancies. | Open/Active | Thomas Lowe, MD |
| Other | BMS 209‐655 | Hodgkin lymphoma molecular profiling and clinical outcomes in U.S Community oncology practice. | Open/Active | Hugo Hool, MD |
Cedars-Sinai Trials
| Disease | Title | Summary | Status | Investigator |
| DCIS/Breast Cancer | COMET AFT-25 | Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial. | Open/Active | Swati Sikaria, MD |
| Urology/Renal Cell Carcinoma | CANTATA- CX-839-008 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC). | Open/Active | Vanessa Dickey, MD |
| Basket Trial | TAPUR- ASCO | TESTING THE USE OF FDA APPROVED DRUGS THAT TARGET A SPECIFIC ABNORMALITY IN A TUMOR GENE IN PEOPLE WITH ADVANCED STAGE CANCER. | Open/Active | Swati Sikaria, MD |